重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白靶向治疗类风湿关节炎的临床疗效观察.pdfVIP

2011年 3月 第 1卷 第 5期 重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白靶向治疗类风湿关节炎的 临床疗效观察 姚巧巧 黄钢红 (武汉钢铁公司职工总医院肾内风湿科，湖北武汉430080) 摘【要】目的 观察重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白(益赛普)联合甲氨蝶呤(MTX)治疗类风湿关节炎的临床 疗效观察及安全性。方法 类风湿关节炎患者 60例，随机分为两组。实验组30例，给予每周两次益赛普25rag注射 ，联合甲 氨蝶呤(MTX)治疗 l2周；对照组 3O例，单用 MTX治疗 l2周。结果 实验组有效率96．7％，对照组有效率66．7％，实验组与 对照组比较差异有统计学意义 (P0．05)。实验组在改善临床症状指标方面明显优于对照组(P0．05)，两组不 良反应发生 率比较无显著统计学意义。结论 益赛普联合MTX治疗与单用 MTX相比可明显改善类风湿关节炎临床症状和实验室指 标，起效迅速，疗效显著，且不 良反应无明显增加。 关【键词】重组人 Ⅱ型肿瘤坏死因子受体一抗体融合蛋白；类风湿性关节炎；甲氨蝶呤 冲 图分类号】R593．22 文【献标识码】A [文章编号】2095～0616(2011)05—20—02 ClinicalStudy on the Effi cacy and Safety of Etanercept in the Treat- mentofActiveRheumatoid Arthritis YAO Qiaoqiao HUANG Ganghong DepartmentofRheumatologyand Kidney Disease，HospitalofWuhan Iron and SteelCompany，Wuhan 430080，China A【bstract1ObjecHveTostudytheefficacysafetyofetanerceptcombinedwithmethotrexate (MTX)therapyforpatientswithactive rheumatoid arthritis．Methods Thesixty patientswiht RA were randomly assigned to twice groups．Th irtywererandomized tothetreat— mentgroupandohterthirtywererandomizedtothecontrolgroup．Thetreatmentrgoupreceivedetanereeptinjection25mgtwiceweekly whileMTX wasadministeredorallyby12week．ThecontrolsubjectsreceivedMTX 10mgorallyonceweeklyby12week．Results Attwe~ht week．hte responseachieved 96．7％ in the etanercept+MTX group and 66．7％ in the controlrgoup．Th eresultsshowed that aJlefficacyendpointsinhteetanercept+MTX rgoupwerebetterthanhtoseofthecontrolsubjects(P0．05)．Buttherewasnosingifi- cantdifferencein hte totaladverse effectsbetween htetwo groups．Conclusion Th eetanereeptgroup has shown arapid efficacy on- setna d asing ificantlybettertherapeutic effectcompared tothatofhteMTX group．Theadverseeffectdoesnotincreaseapparently． K【eywords】Etanercept；Rheumatoidarthritis；MTX 类风湿性关节炎 (RA)是一种以慢性破坏性